AUTL
オートラス・セラピューティクス
AUTL
オートラス・セラピューティクス
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million